SC 13G/A: CONDUIT PHARMACEUTICALS INC.

AI Summary

SC 13G/A filing by CONDUIT PHARMACEUTICALS INC..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securiti

Filing Documents

• ea0216964-13ga2nirland_con.htm (SC 13G/A) — 128KB
• 0001213900-24-086021.txt ( ) — 129KB

From the Filing

SC 13G/A 1 ea0216964-13ga2nirland_con.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Conduit Pharmaceuticals Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 20678X106 (CUSIP Number) October 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). SCHEDULE 13G CUSIP No. 20678X106 1 Names of Reporting Persons Nirland Limited 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization Guernsey Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 8,092,000 (1)(2) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 8,092,000 (1)(2) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 8,092,000 (1)(2) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 8.3% (1)(3) 12 Type of Reporting Person (See Instructions) CO 2 SCHEDULE 13G CUSIP No. 20678X106 1 Names of Reporting Persons Stockton Limited 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization Guernsey Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 8,092,000 (1)(2) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 8,092,000 (1)(2) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 8,092,000 (1)(2) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 8.3% (1)(3) 12 Type of Reporting Person (See Instructions) CO 3 SCHEDULE 13G CUSIP No. 20678X106 1 Names of Reporting Persons The Rowland Master Trust 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization Guernsey Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 8,092,000 (1)(2) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 8,092,000 (1)(2) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 8,092,000 (1)(2) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 8.3% (1)(3) 12 Type of Reporting Person (See Instructions) OO 4 SCHEDULE 13G CUSIP No. 20678X106 1 Names of Reporting Persons Dovet Limited 2 Check the appropriate box if a member of a Group (see instructions) (a) (b) 3 Sec Use Only 4 Citizenship or Place of Organization Guernsey Number of Shares Beneficially Owned by Each Reporting Person With: 5 Sole Voting Power -0- 6 Shared Voting Power 8,092,000 (1)(2) 7 Sole Dispositive Power -0- 8 Shared Dispositive Power 8,092,000 (1)(2) 9 Aggregate Amount Beneficially Owned by Each Reporting Person 8,092,000 (1)(2) 10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) 11 Percent of class represented by amount in row (9) 8.3% (1)(3) 12 Type of Reporting Person (See Instructions) CO (1) Includes (i) 6,092,000 shares of common stock, par value $0.0001 per share (the “ Common Stock ”) of Conduit Pharmaceuticals Inc., formerly Murphy Canyon Acquisition Corp. (the “ Issuer ”) owned by Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L’Or, St Peter Port, GUERNSEY GY1 1QG (“ Nirland Limited ”) and (ii) 2,000,000 shares of Common Stock of the Issuer (the “ Warrant Shares ”), issuable upon exercise of that certain Common Stock Warrant, in substantially the form as the form of warrant filed as Exhibit 4.1 to the Issuer’s Curre

View Full Filing

View this SC 13G/A filing on SEC EDGAR